KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Goodwill & Intangibles (2020 - 2025)

Historic Goodwill & Intangibles for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Q3 2025 value amounting to $484.4 million.

  • Recursion Pharmaceuticals' Goodwill & Intangibles rose 46226.54% to $484.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $484.4 million, marking a year-over-year increase of 46226.54%. This contributed to the annual value of $484.7 million for FY2024, which is 44772.14% up from last year.
  • As of Q3 2025, Recursion Pharmaceuticals' Goodwill & Intangibles stood at $484.4 million, which was up 46226.54% from $505.6 million recorded in Q2 2025.
  • Recursion Pharmaceuticals' Goodwill & Intangibles' 5-year high stood at $505.6 million during Q2 2025, with a 5-year trough of $2.0 million in Q2 2022.
  • Moreover, its 5-year median value for Goodwill & Intangibles was $85.1 million (2024), whereas its average is $133.4 million.
  • Per our database at Business Quant, Recursion Pharmaceuticals' Goodwill & Intangibles plummeted by 1300.26% in 2022 and then skyrocketed by 497733.53% in 2023.
  • Quarter analysis of 5 years shows Recursion Pharmaceuticals' Goodwill & Intangibles stood at $2.2 million in 2021, then decreased by 3.61% to $2.1 million in 2022, then skyrocketed by 4100.24% to $88.5 million in 2023, then soared by 447.72% to $484.7 million in 2024, then fell by 0.07% to $484.4 million in 2025.
  • Its last three reported values are $484.4 million in Q3 2025, $505.6 million for Q2 2025, and $493.9 million during Q1 2025.